These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37139988)

  • 41. Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
    Miyake M; Shimizu T; Nishimura N; Kiba K; Maesaka F; Oda Y; Tachibana A; Tomizawa M; Ohmori C; Matsumura Y; Ichikawa K; Mizobuchi S; Yoshikawa T; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Tanaka N; Fujimoto K;
    Clin Genitourin Cancer; 2022 Apr; 20(2):196.e1-196.e9. PubMed ID: 34916166
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management.
    Parikh M; Powles T
    Am Soc Clin Oncol Educ Book; 2021 Jun; 41():e182-e189. PubMed ID: 34061558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
    Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
    J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Re-Administration of Pembrolizumab for Urothelial Carcinoma after immune-Related Myasthenia Gravis : A Case Report].
    Kurokawa M; Shimizu K; Kitabayashi R; Ogawa K; Okada Y; Kubo K; Yamaguchi D; Okubo K
    Hinyokika Kiyo; 2022 Sep; 68(9):295-300. PubMed ID: 36199208
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
    Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
    Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Furubayashi N; Negishi T; Sakamoto N; Tamura S; Morokuma F; Song Y; Hori Y; Tomoda T; Seki N; Kuroiwa K; Nakamura M
    In Vivo; 2021; 35(5):2869-2874. PubMed ID: 34410980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report.
    Blumendeller C; Boehme J; Frick M; Schulze M; Rinckleb A; Kyzirakos C; Kayser S; Kopp M; Kelkenberg S; Pieper N; Bartsch O; Hadaschick D; Battke F; Stenzl A; Biskup S
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33431630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A case of undifferentiated carcinoma of the bladder treated by combination therapy of surgery, local radiation, and immune checkpoint inhibitors.
    Nakane W; Naito Y; Morishita K; Matsuo K; Ishida S; Matsukawa Y
    Nagoya J Med Sci; 2022 Nov; 84(4):865-870. PubMed ID: 36544596
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma.
    Sadeghi S; Quinn D; Dorff T; Pal S; Groshen S; Tsao-Wei D; Parikh R; Devitt M; Parikh M; Jackovich A; Ruel N; Vogelzang N; Burgess E; Siddiqi I; Gill IS; Lara PN; Dreicer R; Gill PS
    J Clin Oncol; 2023 Jan; 41(3):640-650. PubMed ID: 35984996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
    Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
    Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Checkpoint inhibitors in BCG-unresponsive nonmuscle invasive bladder cancer: can they help spare the bladder?
    El Gharib K; Lilly E; Chebel R
    Immunotherapy; 2021 Sep; 13(13):1105-1111. PubMed ID: 34184569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bladder rupture after pembrolizumab immunotherapy for bladder cancer: a case report.
    Badheeb A; Alkhanbashi O; Rakrouki S; Mahmood T; Alqannas M; Badheeb M; Ahmed F
    Pan Afr Med J; 2022; 42():98. PubMed ID: 36034031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
    Samaha H; Samaha R; Sarkis J; Kattan J
    Immunotherapy; 2021 Mar; 13(4):271-275. PubMed ID: 33397137
    [No Abstract]   [Full Text] [Related]  

  • 58. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
    Nghiem P; Bhatia S; Lipson EJ; Sharfman WH; Kudchadkar RR; Brohl AS; Friedlander PA; Daud A; Kluger HM; Reddy SA; Boulmay BC; Riker A; Burgess MA; Hanks BA; Olencki T; Kendra K; Church C; Akaike T; Ramchurren N; Shinohara MM; Salim B; Taube JM; Jensen E; Kalabis M; Fling SP; Homet Moreno B; Sharon E; Cheever MA; Topalian SL
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879601
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
    Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
    Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.